QUBT Q1 2026 Earnings Transcript

Quantum Computing reported Q1 revenue of $3.7 million, up sharply from $39 thousand, driven mainly by the Lumina Semiconductor and NuCrypt acquisitions, while backlog reached $16 million. The quarter was weighed down by $19.8 million of operating expenses and a $4.1 million net loss, largely from $6 million of M&A costs and underutilized facilities. Management highlighted progress on Fab One, planning for Fab Two, and the first commercial Dirac-3 deployment, but also said gate-based quantum prototypes have not yet begun and key engineering hurdles remain.

Analysis

QUBT is shifting from a pure “story stock” into a balance-sheet-backed roll-up, but the market will likely underappreciate how integration changes the option value of the equity. The acquired photonics assets create a broader addressable market and improve the sales narrative, yet the near-term earnings model is still dominated by low utilization and one-time transaction drag; that means revenue can look exponential while gross profit lags, which is exactly the kind of mismatch that can compress multiples once the novelty fades.

The bigger second-order effect is competitive: by bundling lasers, packaging, testing, and quantum comms, QUBT can win smaller government and defense contracts that would have been uneconomic to source from multiple vendors. That helps it move up the value chain faster than a single-product quantum peer, but it also puts pressure on the acquired businesses to fill capacity; if backlog does not convert within the next 2-3 quarters, underabsorbed overhead will keep margin optics weak and could force another funding/financing discussion despite the cash hoard.

The contrarian takeaway is that the market may be pricing in a scalable manufacturing inflection before the engineering hurdle is actually cleared. The gate-based program still looks like a long-dated call option: high upside if microring quality materially improves over the next 6-12 months, but little evidence yet that prototype risk is past the lab stage. In other words, the company is arguably more investable as a defense/photonics integrator today than as a near-term quantum computer vendor.

Catalyst-wise, the next 1-2 quarters matter more for backlog conversion, gross margin stabilization, and evidence of Fab One throughput than for headline revenue growth. If those metrics do not improve, the market will likely re-rate the acquisition story from “transformational” to “capital intensive and execution-heavy,” especially once M&A costs normalize and there is no more accounting noise to hide the operating leverage problem.

Key Decisions for Investors

• Short-dated tactical long only on a pullback: buy QUBT shares or call spreads only after a post-earnings/press-release selloff of 10%+; target 20-30% upside over 4-8 weeks if backlog converts into incremental contract wins.
• Pair trade: long QUBT / short IONQ over 3-6 months if you want exposure to a photonics/manufacturing narrative; QUBT has more balance-sheet support and less pure science-risk, while IONQ is more exposed to 'show-me' commercialization sentiment.
• Hedge the story risk with QUBT put spreads 3-6 months out; thesis breaks if gross margins remain structurally below 20% and management continues to defer prototype timelines, which could trigger a 25-35% rerating lower.
• For more conservative exposure, prefer a basket long in defense/photonics suppliers over QUBT common; the roll-up thesis has better odds of monetization through component demand than through gate-based quantum commercialization.
• Avoid chasing on gap-ups above recent highs; the asymmetric entry is on evidence of utilization improvement or a disclosed contract conversion, not on acquisition headline momentum.